Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celgene to acquire Avila Therapeutics for $350m plus $575m in milestones

This article was originally published in Scrip

Executive Summary

Celgene is to acquire Avila Therapeutics, a privately held biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, for $350 million in cash, plus up to $195 million for milestones related to its lead product candidate, and a further $380 million in milestones related to the productivity of Avila's Avilomics platform.


Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts